Evidence map›Paper›PMID 40847239›Full record

ReviewCancer treatment and research2025

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.

Prakash Kulkarni, Sravani Ramisetty, Debora Bruno, TingTing Tan, Amartej Merla, Ravi Salgia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Prakash KulkarniDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Sravani RamisettyDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Debora BrunoDepartment of Medical Oncology, City of Hope, Newnan, GA, USA.
TingTing TanDepartment of Medical Oncology, City of Hope National Medical Center, Newport Beach, CA, USA.
Amartej MerlaDepartment of Medical Oncology, Lancaster, CA, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA. rsalgia@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy is a major advancement in the field. It works by stimulating the patient's immune system to recognize and destroy cancer cells. Several different types of cancer immunotherapies have been developed, such as T-cell therapy, immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and many others, which can result in sustainable responses in patients with a wide range of metastatic diseases. Additionally, immunotherapy drugs are being combined with chemotherapy and other targeted therapies to treat a variety of cancer types. Despite the promising results, several challenges remain, such as the almost inevitable immune resistance, drug-related toxicity, and the lack of established and reliable predictive biomarkers to predict toxicity and/or discern a patient's response to immunotherapy. In this chapter, we summarize the mechanisms underlying cancer immunotherapy resistance, especially the contributions of phenotypic plasticity and the underlying non-genetic mechanisms. Furthermore, recent developments in preventing relapses following treatment so that the efficacy of immunotherapy can be improved are also briefly discussed. Finally, the positive impact of an interdisciplinary "Team Medicine" approach to personalize cancer immunotherapy for each patient is highlighted.

Indexed as

Drug Resistance, NeoplasmImmunotherapyNeoplasmsHumansPhenotypeCancer immunotherapyImmunotherapy resistanceNon-genetic mechanismsPhenotype plasticity

Identifiers

PMID40847239

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.